Symposium:
90. HIV State-of-the-Art
Friday, October 4, 2013: 8:30 AM-10:00 AM
Room: The Moscone Center: 120-125

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • summarize the state of HIV cure research
  • outline the latest approaches to managing HIV patients co-infected with hepatitis C to their practice
  • describe advances in HIV treatment

Target Audience: researchers, members-in-training, infectious diseases physicians, HIV specialists, HIV clinicians, fellows, clinicians

Tracks: HIV-STD-TB

Moderator:  Joel Gallant, MD, MPH, FIDSA, Southwest Care Center

Presentations:

8:30 AM
608
Towards and HIV Cure
Steven Deeks, MD

9:00 AM
609

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-100-L02-P

Disclosures:

J. Gallant, Gilead Sciences: Investigator and Scientific Advisor, Consulting fee and Research grant
Bristol-Myers Squibb: Scientific Advisor, Consulting fee
Merck & Co.: Scientific Advisor, Consulting fee
Janssen Therapeutics: Scientific Advisor, Consulting fee
Takara Bio, Inc.: Scientific Advisor, Consulting fee

S. Deeks, Merck: Collaborator, Research grant
Gilead: Consultant, Consulting fee

A. Cox, None

J. J. Eron, Merck: Consultant and Investigator, Consulting fee and Research Grant to UNC School of Medicine (completed)
GSK: Consultant and Investigator, Consulting fee, Research grant and Research Grant to UNC School of Medicine
ViiV: Consultant, Consulting fee
BMS: Consultant, Consulting fee and Grant to UNC School of Medicine
Gilead: Consultant, Consulting fee
Janssen: Consultant, Consulting fee

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.